Monet Howard

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies.

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2020, Blood.

Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A.

P. Kuebler, A. Mahajerin, F. Nissen, 2022, Journal of comparative effectiveness research.

Low immunogenicity of emicizumab in persons with haemophilia A

S. Chebon, A. Kiialainen, K. Yoneyama, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis

S. Robson, V. Jiménez‐Yuste, G. Castaman, 2021, Blood.

Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies

R. Ko, F. Nissen, Fabián Sanabria, 2021, Blood.